NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer

被引：4
|
作者：
Elsada, Ahmed [1 ]
Pearce, Fiona [1 ]
George, Elisabeth [1 ]
Adler, Amanda [1 ]
机构：
[1] Natl Inst Hlth & Care Excellence, Manchester M1 4BT, Lancs, England
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 10期
关键词：
SURVIVAL;
D O I：
10.1016/S1470-2045(14)70346-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1058 / 1059
页数：2
相关论文
共 50 条
  • [1] NICE guidance on enzalutamide for non-metastatic, hormone-relapsed prostate cancer
    Brooke, Adam
    Elsada, Ahmed
    Adler, Amanda
    LANCET ONCOLOGY, 2019, 20 (07): : 906 - 907
  • [2] Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
    不详
    BJU INTERNATIONAL, 2017, 120 (02) : 168 - 184
  • [3] NICE guidance on sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer
    Lovett, Rosemary
    George, Elisabeth
    Adler, Amanda
    LANCET ONCOLOGY, 2015, 16 (04): : 369 - 370
  • [4] NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastases
    Umeweni, Nwamaka
    Knight, Helen
    McVeigh, Gary
    LANCET ONCOLOGY, 2016, 17 (03): : 275 - 276
  • [5] Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel
    Lovett, Rosemary
    Kelly, Victoria
    Goodall, Melinda
    Adler, Amanda I.
    LANCET ONCOLOGY, 2016, 17 (07): : 872 - 873
  • [6] The management of hormone-relapsed prostate cancer
    Clarke, NW
    BJU INTERNATIONAL, 2003, 92 (08) : 860 - 868
  • [7] Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective
    Emma L. Simpson
    Sarah Davis
    Praveen Thokala
    Penny R. Breeze
    Peter Bryden
    Ruth Wong
    PharmacoEconomics, 2015, 33 : 1187 - 1194
  • [8] Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective
    Simpson, Emma L.
    Davis, Sarah
    Thokala, Praveen
    Breeze, Penny R.
    Bryden, Peter
    Wong, Ruth
    PHARMACOECONOMICS, 2015, 33 (11) : 1187 - 1194
  • [9] Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Kearns, Benjamin
    Pandor, Abdullah
    Stevenson, Matt
    Hamilton, Jean
    Chambers, Duncan
    Clowes, Mark
    Graham, John
    Kumar, M. Satish
    PHARMACOECONOMICS, 2017, 35 (04) : 415 - 424
  • [10] Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Benjamin Kearns
    Abdullah Pandor
    Matt Stevenson
    Jean Hamilton
    Duncan Chambers
    Mark Clowes
    John Graham
    M. Satish Kumar
    PharmacoEconomics, 2017, 35 : 415 - 424
12345